(17.4%) and benign prostate hyperplasia in 233/304 (76.7%) patients. Mean catheter time was 2.2d and mean hospitalization stay 2.4d.
INTRODUCTION AND OBJECTIVES:
Chronic Prostatitis/ Chronic Pelvic Pain Syndrome (CP/CPPS) is a taxing disorder that is characterized by development of persistent pelvic pain in men of any age. Effective therapeutic treatments are scarce, due to a poorly defined etiology and pathogenesis of CP/CPPS. Although several studies suggest that the transient receptor potential vanilloid 1 (TRPV1) channel is involved in various pathways of chronic pain and a new generation of compounds that target the TRPV1 channel seem promising, the TRPV1 channel has not been linked to chronic pelvic pain in CP/CPPS. METHODS: Male C57BL/6J (B6) and TRPV1 knockout (TRPV1 KO) mice (5-7 weeks old) were used to induce experimental autoimmune prostatitis (EAP) and compared to respective control cohorts. The prostate lobes, dorsal root ganglia (DRG), and spinal cord were excised at day 20. The prostate lobes were assessed for inflammation, TRPV1 expression, and mast cell activity by blinded observers. The lumbosacral region of the DRG and spinal cord were measured for phosphorylation of ERK1/2 (p-ERK1/2). In addition, B6 mice with EAP received intraurethral administration of a TRPV1 antagonist at day 20 (repeated every two days) and we assessed the development of pain compared to control cohorts at days 20, 25, 30, and 35 . RESULTS: Our data showed that B6 mice with EAP developed markedly enhanced pelvic tactile allodynia at days 7, 14, and 20. Surprisingly, the data revealed that TRPV1 KO mice with EAP do not develop pelvic tactile allodynia between days 7 to 20 and demonstrate a similar tactile response to respective controls. The dorsal and lateral prostate (DLP) lobes excised from B6 mice and TRPV1 K0 with EAP showed increased inflammation. Also, the DLP from B6 mice with EAP contained similar levels of TRPV1 compared to controls. In contrast, B6 mice with EAP showed a significant increase of mast cell activation. Interestingly, the DLP lobes from TRPV1 KO mice with EAP showed a lack of mast cell activation. Next, we observed a significant increase of p-ERK1/2 in the lumbosacral region of the DRG and spinal cord of B6 mice with EAP at day 20; however, p-ERK1/2 expression was unchanged in TRPV1 KO mice with EAP. In a separate experiment, we administered a TRPV1 antagonist peptide intraurethrally to the prostate and blunted the progression of pelvic tactile allodynia in mice with EAP.
CONCLUSIONS: The TRPV1 channel is a key mediator in persistent pelvic pain in EAP and intraurethral delivery of a TRPV1 antagonist peptide to the prostate may be a novel approach to alleviate chronic pelvic pain. 
MP54-02 THE ADDED VALUE OF A GENOMIC SIGNATURE IN NON-ORGAN-CONFINED PROSTATE CANCER
Alberto Martini*, Dmitry Rykunov, Shivaram Cumarasamy, John P. Sfakianos, Ardeshir R. Rastinehad, Kenneth G. Haines III, Sujit S. Nair, Boris Reva, Ashutosh K. Tewari, New York, NY INTRODUCTION AND OBJECTIVES: The ability to predict non-organ-confined prostate cancer (PCa), as either in the form of extracapsular extension (ECE) or seminal vesicle invasion (SVI) is of pivotal importance for patient counseling and surgical planning. In an era of precision medicine, we aimed to identify genes associated with ECE and SVI and to build a predictive model. METHODS: Data from 494 patients with complete transcriptomic profile and SCAN-normalized expression of coding and noncoding genes was identified from our single-center prospectively maintained database. All the patients underwent multiparametric MRI before receiving robot assisted radical prostatectomy. The tissue used for transcriptomic profiling was obtained from the neoplastic area with the highest Gleason Group on the pathology specimen. First, in order to develop the genomic signature, the data was split into a training (50%), test (25%) and validation (25%) cohort.
Second, a multivariable binary logistic regression was built to predict alternatively ECE and SVI. Variable included were: PSA, biopsy Gleason grade, highest percentage core involvement, clinical stage from mpMRI (organ-confined vs. capsule abutment vs. ECE vs. SVI) and index lesion's greatest diameter.
The tumor transcriptional profiles were used to evaluate for biomarkers and to construct genomic signatures for better a classification of disease subtypes, measured by the increase in AUC, with associated 95%CI.
RESULTS: Median (IQR) age at surgery was 53 (57-68) yrs, median (IQR) PSA was 6.5 (5.1-10.2) ng/ml. Overall, 166 (34%) and 62 (13%) patients had ECE and SVI on final pathology, respectively.
A signature based on the gene expression values of six coding genes was constructed for the prediction of ECE and SVI. In the validation cohort, the AUC was 0.72 and 0.76 for predicting ECE and SVI, respectively. All variables included in the multivariable model emerged as predictors of both ECE and SVI. The AUC of the models based on clinical parameters, biopsy and mpMRI data was 0.81 (95%CI: 0.77-0.85) and 0.84 (95%CI: 0.79-0.89) for ECE and SVI, respectively. Adding the signatures to the multivariable models improved the discrimination in predicting ECE to p[0.04) .
CONCLUSIONS: By integrating clinical, biopsy, mpMRI and genomic data we developed two models that accurately allow for the prediction of non-organ-confined PCa. Our models might serve in patient counseling, in the selection of candidates for potential novel neoadjuvant treatments and for surgical planning.
